Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May;53(4):959-964.
doi: 10.1007/s11239-021-02615-z. Epub 2021 Nov 22.

Evaluation of heparin infusion rates in patients with intravenous drug misuse

Affiliations
Multicenter Study

Evaluation of heparin infusion rates in patients with intravenous drug misuse

Kenneth Barga et al. J Thromb Thrombolysis. 2022 May.

Abstract

To evaluate the hypothesis that patients with a history of intravenous drug misuse (IVDM) initiated on weight-based heparin infusions require higher than expected infusion rates to achieve therapeutic activated partial thromboplastin time (aPTT). This study is a multicenter, retrospective chart review of patients with a history of IVDM who were admitted to an acute care site between 10/1/2015 and 9/30/2020 and treated with continuous heparin infusions. Patients were identified using ICD9 and ICD10 codes and included if they had a documented history of IVDM within the past six months. Variables of particular interest included: median heparin infusion rates to maintain therapeutic aPTT, average time to reach therapeutic aPTT, and International Society of Thrombosis and Haemostasis Criteria for moderate to severe bleeding. Of the 41 patients who met the inclusion and exclusion criteria, 39 achieved therapeutic aPTT while on a weight-based heparin infusion. All heparin infusions were initiated at a rate of 18 units/kg/hr then titrated per institutional heparin infusion protocols. The mean time to therapeutic aPTT was 38.48 h ± 26.4 h with a mean infusion rate of 27.64 ± 7.14 units/kg/hr. To maintain therapeutic anticoagulation, infusion rates 150% higher than the initial rate were required. Of the 39 patients who achieved therapeutic aPTT, 85% (33) met criteria for heparin resistance, defined as greater than 35,000 units of heparin daily. No statistical significance could be derived from this retrospective chart review as therapeutic heparin rates were evaluated in comparison to initial infusion rate, rather than a control group. The findings in this study demonstrate a possible clinical association of the reduced antithrombin activity previously described in opiate misusers. To efficiently achieve therapeutic anticoagulation, it may be appropriate to consider use of heparin antiXa monitoring in place of aPTT or utilization of increased initial heparin infusion rates.

Keywords: Anticoagulation; Antithrombin; Heparin; Intravenous drug misuse; Pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

None of the four authors, Kenneth Barga, Katherine Crawford, Mallory Faherty, nor Adam Smith have any conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Resultant sample population based on inclusion/exclusion criteria
Fig. 2
Fig. 2
Heparin infusion rate and time to therapeutic aPTT for all patients who achieved therapeutic aPTT

References

    1. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094–1096. doi: 10.1161/hq0701.093686. - DOI - PubMed
    1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S–94S. doi: 10.1378/chest.119.1_suppl.64S. - DOI - PubMed
    1. Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol. 1990;3:531–544. doi: 10.1016/s0950-3536(05)80017-4. - DOI - PubMed
    1. Samuel S, Allison TA, Sharaf S, et al. Antifactor Xa levels vs activated partial thromboplastin time for monitoring unfractionated heparin. J Clin Pharm Ther. 2016;41(5):499–502. doi: 10.1111/jcpt.12415. - DOI - PubMed
    1. Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7–8):861–868. doi: 10.1345/aph.1Q161. - DOI - PubMed

Publication types

LinkOut - more resources